Dosing & Uses
Myasthenia Gravis
Pending FDA approval for treatment of adults with generalized myasthenia gravis (gMG) who are acetylcholine receptor antibody positive (AChR-Ab+)
Next:
Pharmacology
Mechanism of Action
Macrocyclic peptide that blocks cleavage of complement C5 into C5a and C5b which occurs as a consequence of activation of the classical, alternative, or lectin pathways
Complement-mediated damage to the neuromuscular junction is triggered by activity of antibodies directed toward AChR
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
